What Is Calprotectin Fecal? Normal vs Optimal Range Explained

Many laboratories report fecal calprotectin as "normal" up to 200 μg/g, but meaningful gut inflammation is already present at much lower levels. Calprotectin is released by neutrophils that migrate into the intestinal wall during inflammation—the more neutrophils present, the higher the calprotectin. The CTD maps over 180 compound interactions with calprotectin-related inflammatory genes, reflecting the marker's sensitivity to dietary, microbial, and pharmacological influences on gut health. A value between 50 and 200 μg/g sits in a diagnostic gray zone: too high to dismiss as completely normal, too low to diagnose IBD with confidence. Repeat testing in four to six weeks helps distinguish a transient elevation (from NSAIDs, infection, or dietary factors) from a persistent one requiring colonoscopy.

PubMed indexes over 5,400 publications on fecal calprotectin, with the test's primary clinical value being its ability to differentiate organic intestinal disease (IBD, infection, colorectal cancer) from functional disorders (irritable bowel syndrome). In meta-analyses, fecal calprotectin above 50 μg/g has a sensitivity of approximately 93 percent and specificity of 96 percent for distinguishing IBD from IBS in symptomatic patients. This makes it one of the most valuable non-invasive tests in gastroenterology—a normal calprotectin in a patient with chronic diarrhea and abdominal pain strongly argues against IBD and may spare them an unnecessary colonoscopy. A normal calprotectin does not, however, rule out IBS, celiac disease, or microscopic colitis.

For patients with established IBD, serial calprotectin monitoring tracks disease activity more reliably than symptoms alone. Many IBD patients experience subclinical mucosal inflammation (detectable by calprotectin) even when they feel well—a state that predicts future flares and progressive bowel damage if not addressed. Achieving a calprotectin below 150 μg/g is associated with endoscopic remission and better long-term outcomes. Some gastroenterologists now target calprotectin below 50 μg/g as deep remission, though this aggressive target is not universally achieved. Home stool collection makes calprotectin monitoring practical for patients—no fasting, no blood draw, and results are stable at room temperature for up to a week.